CagriSema vs Tirzepatide: Amylin/GLP-1 vs GIP/GLP-1 for Maximum Weight Loss
Evidence-based comparison of CagriSema (amylin + GLP-1) and tirzepatide (GIP + GLP-1) for obesity, including REDEFINE and SURMOUNT trial data.
| Category | CagriSema | Tirzepatide | Advantage |
|---|---|---|---|
| Mechanism of Action | Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets amylin + GLP-1 receptors for complementary appetite suppression, gastric emptying delay, and leptin resensitization. | Dual GIP/GLP-1 receptor agonist in a single molecule. Targets GIP + GLP-1 receptors for synergistic effects on insulin secretion, appetite suppression, and metabolic improvement. ~5-fold potency at GIPR relative to native GIP. | Comparable |
| Weight Loss Efficacy | REDEFINE 1 demonstrated 20.4% mean weight loss at 68 weeks. 60% achieved at least 20% loss, and 23% achieved 30% or more. However, CagriSema fell short of Novo Nordisk's initial 25% weight loss target. | SURMOUNT-1 demonstrated 20.9% mean weight loss at 15 mg at 72 weeks. Up to 36% achieved 25% or more weight loss. The highest FDA-approved weight loss efficacy. | Comparable |
| Type 2 Diabetes Efficacy | REDEFINE 2 showed 13.7% weight loss and 73.5% of T2D patients achieving HbA1c of 6.5% or less at 68 weeks. | SURPASS trials showed HbA1c reductions of up to 2.58% (15 mg) with 52% achieving normal HbA1c below 5.7%. FDA-approved for T2D (Mounjaro). | Tirzepatide |
| Safety and Tolerability | GI adverse events in 72.5% of patients. Higher rate reflects dual amylin + GLP-1 activation. Most events transient and mild-moderate. Filed for FDA approval; limited post-marketing data. | Nausea 12-33%, diarrhea 12-21%, vomiting 5-13%. FDA-approved since 2022 with growing post-marketing experience. Comparable or better GI tolerability vs semaglutide alone in SURPASS-2. | Tirzepatide |
| Dosing and Formulation | Once-weekly subcutaneous injection. Fixed-dose combination pen containing both cagrilintide and semaglutide. Single injection, two mechanisms. | Once-weekly subcutaneous injection via pre-filled pen. Six dose levels (2.5-15 mg) for flexible titration. Single-dose hidden-needle pens. | Comparable |
Introduction#
CagriSema (cagrilintide + semaglutide, Novo Nordisk) and tirzepatide (Eli Lilly) represent the pinnacle of next-generation obesity pharmacotherapy, both achieving approximately 20% weight loss through different dual-mechanism approaches. This comparison is arguably the most important in metabolic medicine heading into 2026, as it pits the two pharmaceutical giants against each other in the competition for the best-in-class obesity treatment.
CagriSema combines amylin receptor agonism (cagrilintide) with GLP-1 agonism (semaglutide). Tirzepatide combines GIP receptor agonism with GLP-1 agonism in a single molecule. No head-to-head trial has been conducted between them.
Mechanism of Action Comparison#
CagriSema#
CagriSema delivers two separate peptides in one injection. Semaglutide activates GLP-1 receptors (appetite suppression, glucose homeostasis). Cagrilintide activates amylin receptors (AMY1-3) in the brainstem (food intake reduction, leptin resensitization, gastric emptying delay). The amylin pathway is distinct from both GLP-1 and GIP signaling.
Tirzepatide#
Tirzepatide is a single 39-amino acid molecule that simultaneously activates GIP and GLP-1 receptors. GIPR activation potentiates insulin secretion, may improve fat distribution, and enhances central appetite regulation through mechanisms complementary to GLP-1R signaling.
Different Dual Approaches#
| Feature | CagriSema | Tirzepatide |
|---|---|---|
| Pathways | Amylin + GLP-1 | GIP + GLP-1 |
| Molecules | Two (combination) | One (single molecule) |
| Second target | Amylin receptors (AMY1-3) | GIP receptor |
| Leptin sensitization | Yes (via amylin) | Not established |
| CV outcomes data | No (semaglutide alone has SELECT) | CVOT pending |
Weight Loss Comparison#
| Outcome | CagriSema (REDEFINE 1) | Tirzepatide (SURMOUNT-1) |
|---|---|---|
| Mean weight loss | 20.4% at 68 weeks | 20.9% at 15 mg, 72 weeks |
| Achieved 20%+ | 60% | ~50% (15 mg) |
| Achieved 25%+ | ~35% | 36% (15 mg) |
| Population | Without T2D | Without T2D |
| Comparator | Placebo, sema alone, cagri alone | Placebo |
Cross-trial comparison is limited by differences in population, duration, dose escalation, and trial design. A head-to-head trial would be needed for definitive comparison.
Safety Comparison#
| Parameter | CagriSema | Tirzepatide |
|---|---|---|
| Any GI event | 72.5% | ~50-60% |
| Approval status | Filed for FDA | FDA-approved |
| Post-marketing data | None | Growing (since 2022) |
| Class warnings | GLP-1 + amylin class | GLP-1 class |
Key Differences Summary#
- Weight loss: Comparable (~20-21%), no head-to-head trial
- Mechanism: Amylin/GLP-1 (CagriSema) vs GIP/GLP-1 (tirzepatide)
- Molecules: Two-peptide combination vs single dual-agonist molecule
- Approval: Tirzepatide is FDA-approved; CagriSema is filed
- T2D evidence: Tirzepatide has more extensive T2D trial data
- GI tolerability: CagriSema has higher overall GI event rates
Conclusion#
CagriSema and tirzepatide represent different strategies to the same goal: surpassing GLP-1-only weight loss. Both achieve approximately 20% weight reduction, making them the most effective anti-obesity pharmacotherapies. Tirzepatide has the current advantage of FDA approval and growing real-world experience. CagriSema's imminent approval will create true competition at the top of the obesity treatment landscape. The absence of a head-to-head trial means that prescribing decisions will initially be guided by availability, formulary coverage, individual tolerability, and prescriber familiarity rather than definitive comparative efficacy data.
Detailed Category Analysis#
Mechanism of Action#
CagriSema: Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets amylin + GLP-1 receptors for complementary appetite suppression, gastric emptying delay, and leptin resensitization.
Tirzepatide: Dual GIP/GLP-1 receptor agonist in a single molecule. Targets GIP + GLP-1 receptors for synergistic effects on insulin secretion, appetite suppression, and metabolic improvement. ~5-fold potency at GIPR relative to native GIP.
Advantage: Neither (tie)
Weight Loss Efficacy#
CagriSema: REDEFINE 1 demonstrated 20.4% mean weight loss at 68 weeks. 60% achieved at least 20% loss, and 23% achieved 30% or more. However, CagriSema fell short of Novo Nordisk's initial 25% weight loss target.
Tirzepatide: SURMOUNT-1 demonstrated 20.9% mean weight loss at 15 mg at 72 weeks. Up to 36% achieved 25% or more weight loss. The highest FDA-approved weight loss efficacy.
Advantage: Neither (tie)
Type 2 Diabetes Efficacy#
CagriSema: REDEFINE 2 showed 13.7% weight loss and 73.5% of T2D patients achieving HbA1c of 6.5% or less at 68 weeks.
Tirzepatide: SURPASS trials showed HbA1c reductions of up to 2.58% (15 mg) with 52% achieving normal HbA1c below 5.7%. FDA-approved for T2D (Mounjaro).
Advantage: Tirzepatide
Safety and Tolerability#
CagriSema: GI adverse events in 72.5% of patients. Higher rate reflects dual amylin + GLP-1 activation. Most events transient and mild-moderate. Filed for FDA approval; limited post-marketing data.
Tirzepatide: Nausea 12-33%, diarrhea 12-21%, vomiting 5-13%. FDA-approved since 2022 with growing post-marketing experience. Comparable or better GI tolerability vs semaglutide alone in SURPASS-2.
Advantage: Tirzepatide
Dosing and Formulation#
CagriSema: Once-weekly subcutaneous injection. Fixed-dose combination pen containing both cagrilintide and semaglutide. Single injection, two mechanisms.
Tirzepatide: Once-weekly subcutaneous injection via pre-filled pen. Six dose levels (2.5-15 mg) for flexible titration. Single-dose hidden-needle pens.
Advantage: Neither (tie)
Summary and Verdict#
CagriSema and tirzepatide achieve remarkably similar weight loss (20.4% vs 20.9%) through fundamentally different dual mechanisms -- amylin/GLP-1 versus GIP/GLP-1. This positions them as the two leading next-generation obesity treatments. Tirzepatide has the advantage of FDA approval and growing real-world experience. CagriSema is filed for approval and represents Novo Nordisk's competitive response. Without a head-to-head trial, definitive superiority cannot be established. The choice may ultimately depend on individual response, tolerability, and prescriber experience.
Best For Recommendations#
Currently Available Treatment#
Recommendation: Tirzepatide
Reason: Tirzepatide is FDA-approved and available as Mounjaro (T2D) and Zepbound (obesity). CagriSema is not yet approved. For patients who need treatment now, tirzepatide is the accessible option.
Novo Nordisk Patients Seeking Upgrade#
Recommendation: CagriSema
Reason: Patients already on semaglutide (Wegovy) who need greater weight loss can potentially upgrade to CagriSema within the Novo Nordisk ecosystem once approved, leveraging the same GLP-1 component plus added amylin agonism.
Type 2 Diabetes Focus#
Recommendation: Tirzepatide
Reason: Tirzepatide has 5 SURPASS T2D trials, FDA approval for diabetes (Mounjaro), and demonstrated superiority over semaglutide in SURPASS-2. CagriSema's T2D data is more limited.
Maximum Responder Rate (20%+ Loss)#
Recommendation: CagriSema
Reason: 60% of CagriSema patients achieved at least 20% weight loss in REDEFINE 1, a higher responder rate than tirzepatide's across-trial data, though cross-trial comparison has limitations.
Further Reading#
Which Is Better For...
Currently Available Treatment
Tirzepatide
Tirzepatide is FDA-approved and available as Mounjaro (T2D) and Zepbound (obesity). CagriSema is not yet approved. For patients who need treatment now, tirzepatide is the accessible option.
Novo Nordisk Patients Seeking Upgrade
CagriSema
Patients already on semaglutide (Wegovy) who need greater weight loss can potentially upgrade to CagriSema within the Novo Nordisk ecosystem once approved, leveraging the same GLP-1 component plus added amylin agonism.
Type 2 Diabetes Focus
Tirzepatide
Tirzepatide has 5 SURPASS T2D trials, FDA approval for diabetes (Mounjaro), and demonstrated superiority over semaglutide in SURPASS-2. CagriSema's T2D data is more limited.
Maximum Responder Rate (20%+ Loss)
CagriSema
60% of CagriSema patients achieved at least 20% weight loss in REDEFINE 1, a higher responder rate than tirzepatide's across-trial data, though cross-trial comparison has limitations.
Continue Your Research
Get comparison updates
We publish new head-to-head comparisons regularly. Subscribe to see them first.
Frequently Asked Questions About CagriSema vs Tirzepatide: Amylin/GLP-1 vs GIP/GLP-1 for Maximum Weight Loss
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.